Prescription Drugs · Oncology Therapeutics
Bristol Myers Squibb: Funding & valuation
Bristol Myers Squibb has $277.9M paid in by investors, lenders and donors.
Financials
Revenue of $48.2B in 2025. −0.2% on the year before. Net income $7.1B.
$48.2BRevenue2025 · −0.2%
$7.1BNet income2025 · +178.8%
30,000Employees2019
Revenue by yearas filed, with the net income
Sources: SEC
Money
Bristol Myers Squibb has $277.9M paid in by investors, lenders and donors.
$277.9MPaid in
$277.9MDonations received
$3.3BIncome taxes paidFY2025
$5BDividends and buybacksFY2025
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
$79.1MPaid
$861kPaid
$20.5MPaid
2 more records: amounts, dates and sources of every round, loan and commitmentProUnlockor this company alone for 30 days · 50 credits
Money out
$42.6MPaid
$86.9MPaid
$45.4MPaid
3 more records: amounts, dates and sources of every round, loan and commitmentProUnlockor this company alone for 30 days · 50 credits
Fund markswhat funds reporting to the SEC say their stakes are worth
Funds reporting to the SEC (2) valued their Bristol Myers Squibb stock at $184 as of Oct 2025.
Marks by fund: shares held, the price a share, the change since the last quarterPremiumUnlockor this company alone for 30 days · 50 credits
From its filingssec.gov ↗
| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Income taxes paid | $4.3B | $3.9B | $3.3B |
| Dividends paid | $4.7B | $4.9B | $5B |
| Shares bought back | $5.2B | – | – |
| Capital expenditure | $1.2B | $1.2B | $1.3B |
| Stock-based compensation | $518M | $507M | $553M |
| Acquisitions, net of cash | $1.2B | $21.8B | $3.9B |
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
